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Introduction
A biochip is an electronic chip that can be used to control and automate biochemistry reactions. Instead of mixing uids together based on milliliters and liters in test tubes and beakers, biochips can perform many of the same reactions by manipulating nano-liter-sized quantities of uid on a small lab-on-chip device. Micro uidic lab-on-chips have been designed to execute a multitude of di erent biochemical applications, including in-vitro diagnostics and immunoassays, used in clinical pathology and integrate the experience of VLSI and incubation, can be carried out using a two-dimensional array of electrodes and nano-liter volumes of liquid [7] .
In a DMFB, activation sequence of electrodes is controlled by a micro-controller, normally based on the target chemical experiment. According to microcontroller pins allocated to electrodes, two categories of addressing methods are proposed: direct addressing and pin-constrained methods. Direct-addressing biochips (DA-DMFB) provide independent control pin over each electrode that increases the exibility. These devices are very costly (or even infeasible) because the large number of control inputs and high wiring complexity can increase the number of Printed Circuit Board (PCB) layers [8] . Pin-constrained (PC-DMFB) technique was proposed to solve the cost problem in the DA-DMFBs. In the PC-DMFBs, electrodes are grouped, and each cluster has a common external pin. Most important methods of these categories are described in the following sections.
So far, various architectures and algorithms have been presented for the implementation of digital micro udic biochips. However, these architectures have di erent challenges and face serious problems with exibility, con guration capabilities, large number of control pins, and long time running bioassays. For example, the application speci c architecture is designed for a speci c application, and this kind of biochip cannot be generalized to other bioassays [9] . The Generalpurpose [8] and Recon gurable architectures [10] are also ine cient and have a large number of control pins and, consequently, higher cost. The pin-constrained architecture reduces the pin numbers, yet does not have su cient exibility [11] . The eld-programmable pinconstrained DMFB architecture [6] is presented as a general-purpose architecture to decrease the number of controlling pins and the corresponding costs, yet lacks the exibility and requires more time to run large bioassays.
FPGA is a successful platform in microelectronics in terms of exibility, parallelism, and cost/performance tradeo . In this paper, a new FPGAinspired architecture is proposed for digital micro uidic biochips to increase the DMFBs in terms of con gurability, degree of parallelism, and the chip usability.
The paper is structured as follows. In Section 2, various types of biochips and their architectures are described. In Section 3, proposed architecture and physical design algorithms for digital micro uidic biochip are presented. In Section 4, experimental results are presented, and Section 5 concludes the paper.
An overview of biochips
A biochip is a collection of miniaturized test sites (microarrays or micro uidic grid) arranged on a solid substrate that provides a platform for performing many chemical tests in order to achieve higher throughput and exibility. Similar to a computer chip that can perform millions of mathematical operations in one second, a biochip can perform thousands of biological reactions, such as decoding genes in few seconds. Biochips are divided into two categories: micro uidicbased biochips and Microarray-based biochips.
Microarray biochips
The DNA microarray is a piece of glass, plastic or silicon substrate whose DNA pieces are a xed in a microscopic array. These DNA segments act as DNA probes in detecting genetic sequences of a biological sample simultaneously. Similarly, in protein arrays, large quantities of capture agents (like monoclonal antibodies) act as detectors and help determine the presence and/or amount of proteins in biological samples, e.g., blood. GeneChip DNA array from A ymetrix, DNA microarray from In neon A, and nanochip microarray from nanogen are few DNA microarray technique-based biochips available on the market [2] . A major disadvantage of DNA and protein arrays is that once these chips are synthesized, they are neither con gurable nor scalable. Moreover, there is no facility to carry out sample preparation in this kind of biochips.
Micro uidic biochips
In recent years, micro uidic-based biochips have become popular for biochemical analysis. These miniaturized micro uidic-based biochips can perform enzymatic analysis (e.g., glucose, lactate, and private assays of human physiological uids like saliva, urine, etc.), massive parallel DNA analysis, automated drug discovery, and toxicity monitoring. These biochips can be termed as lab-on-a-chip as it replaces highly repetitive laboratory tasks by replacing cumbrous laboratory equipment with composite micro-system [2] .
Mainly, two types of micro uidic-based biochips, i.e., continuous-ow-based and droplet-based micro uidic biochips, are described below.
2.2.1. Continuous-ow micro uidic biochips As mentioned before, the technology of these chips is based on the manipulation of continuous liquid ow through micro-fabricated channels. External pressure sources, integrated mechanical micro-pumps or electrokinetic mechanisms are used for the actuation and manipulation of liquid ow [2] .
Continuous ow biochips are useful in carrying out simple biochemical applications, which require less complicated uid manipulation. Because of the structure of these biochips, it becomes very di cult to integrate and scale these kinds of micro uidic chips. The recon gurability of these chips is very poor because of the permanent etching of the microstructures. More-over, fault tolerance capability is very poor because of the poor recon gurability of this technology.
Digital micro uidic biochips
In digital micro uidic biochips, the liquids in the form of discrete droplets are controlled independently and concurrently over a 2D array of electrodes. The prime advantages of these biochips include recon gurability, ease of integration, high-level automation, and ability to scale. The assays can be broken down to a few basic operations that can be easily de ned and automated. A group of cells can be recon gured to perform di erent activities in di erent phases of the experiment. Due to these properties, biochips can be considered programmable micro uidic processors [10, 11] .
In DMFBs, droplets can be manipulated using chemical, thermal, acoustical, and electrical principles [12] , and there are two kinds of electrical methods for moving the droplets: Di-electrophoresis (DEP) [13, 14] and Electro-Wetting On-Dielectric (EWOD) [2] . Figure 1 represents an EWOD-based micro uidic biochip and its basic unit cell. The detailed fabrication process of a basic unit cell in EWOD-based DMFB is described in [2, 7, 15] .
The main uidic processing carried out on digital micro uidic biochips is as follows [16, 17] : -Creation: To take a certain amount of liquid from a reservoir to form droplets of a given size, Figure 2 The advantages of DMFBs over huge and heavy systems include design exibility, higher sensitivity, smaller size, lower cost, less sample size and reagents volume, and lower power consumption.
Various architectures of DMFBs
Various architectures have been proposed for DMFBs. Since the structure and features of these architectures are e ective in the concept of the paper, these architectures are described in the following subsections.
Application speci c architectures
In this kind of digital biochips, type and number of modules, their location, and traveling path of the droplets are planned and xed at the design time for a speci c application. It is implied that spatial assignment (location of each operation) and temporal assignment (the activation time of each operation) should be done at the design time. The important aspect in this architecture is that a special chip should be designed for each assay, which is not a ordable and reasonable as the price [9] . A sample of these biochips is shown in Figure 3 . This biochip is designed and fabricated for a speci c application (recognition of Malaria) and cannot be reprogrammed for other applications [9] .
General-purpose architectures
In this type of architectures, spatial assignment (location of mix, detect, store, and other modules) should be determined at the design time; however, temporal assignment (scheduling management) should be decided at the usage time. Figure 4 represents a sample of a general-purpose biochip.
As can be seen in Figure 4 , routing between modules (dark columns and rows) has been considered at the design time and cannot be changed at the time of executing [8] . The light areas show working parts where only splitting and mixing operations can be done. In this architecture, only splitting and mixing operations can be done in parallel; then, results should be sent to external sources [8] .
Recon gurable architectures
In recon gurable architectures, place and time attributions are determined at the usage time. Position of detect modules and I/O ports should be classi ed and xed at the design time; however, the attributions of other modules should be resolved after the design time. Figure 5 shows recon gurable architecture, where all areas of the chip are covered with electrode, and each one should be controlled by a pin. In this architecture, the electrodes, I/O ports, and detection modules are shown. The main operations, such as mix and store, can be created in every location on two arrays of electrodes [10] .
Pin-Constrained Digital Micro uidic Biochip (PC-DMFB)
Increasing the number of electrodes and pins of the previous architectures leads to the increasing number of control pins, PCB (Printed Circuit Board) layers, and cost of these biochips. Therefore, a pin-constrained solution was proposed in [7, 11] . The basic idea of this solution is to partition electrodes into several groups and connect each group of electrodes to a single control pin. Figure 6 constrained addressing. In these gures, the same numbers indicate that the corresponding electrodes are connected and controlled by the same pin. Although the number of control pins can be reduced, the pinconstrained solution has low exibility, because it is usually speci c to a micro uidic application.
Field-Programmable Pin-Constrained DMFB (FPPC DMFB)
In [6] , a general-purpose architecture is presented to decrease the number of controlling pins and the corresponding costs. In this method, place attribution is done at the design time, while the time attribution is determined at the usage time. Considerable areas of the chip surface are unusable, which are used for module separation. Moreover, I/O sources can be located anywhere in around of the biochip. The problem addressed for this architecture is that larger chips are required for large assays. Figure 7 shows an example of FPPC architecture.
Analysis and comparison of architectures
In the previous section, various types of digital biochip architectures were described in detail. The main advantages of special-purpose biochips include simplicity of design and implementation as well as low production and reagent costs. However, this biochip is application-speci c without recon gurability and programmability capabilities. The general-purpose biochips resolved speci c-purpose problems; however, they are not fully-programmable because the locations of modules are pre-designed while routing is done for a speci c problem. The next generation of biochips is presented with a fully recon gurable architecture to improve the exibility of biochips. This architecture is a two-dimensional array of controllable electrodes, whose electrode is controlled by an external pin; in addition, decreasing the number of pins is very critical in feasibility of biochip construction. For large assays, such devices make huge wiring complexity that requires costly multi-layer PCBs. In contrast, pin-constrained DMFBs reduce the wiring complexity, yet reduce the exibility of droplet coordination. FPPC DMFBs have been proposed to solve the problems of PC. FPPC Figure 6 . Two electrode-addressing solutions: (a) Direct-addressing [8] and (b) pin-constrained [7] . Figure 7 . Field-programmable pin-constrained DMFB [6] .
DMFBs use a routing column among modules (SSD, MIX,..) to reduce exibility. In addition, parallelism is impossible.
The proposed architecture and design ow
As mentioned before, a new architecture is proposed to maintain a reasonable trade-o between e ciency and exibility. The main objectives of the proposed approach are as follows: -Reducing the execution time of large-scaled assay operations; -Parallelizing the operations as much as possible; -Reducing the number of pins; -Increasing the exibility and programmability of micro uidic platform. In the following subsections, the proposed architecture is described, and then the corresponding design ow is expressed.
The proposed architecture
In the previous sections, various architectures and their problems were mentioned. In this section, a new architecture for micro uidic biochip is presented which is inspirited from the conventional FPGAs. The proposed architecture, which is actually the improved architecture in [18] , is induced from FPGA architecture, because FPGAs make a good trade-o between e ciency and exibility, and using the semantics of FPGA architecture in micro uidic biochips will be useful. The proposed architecture can be con gured for each assay or biochemical evaluations without new fabrication of the chip. An FPGA contains twodimensional arrays of logic blocks and interconnections between logic blocks. Both the logic blocks and interconnects are programmable. Logic blocks can be programmed to implement the desired functions, and an interconnect is programmed using the switch boxes to realize a speci c connection scheme between the logic blocks. General architecture of an FPGA is shown in Figure 8 .
The main objective of the proposed architecture is to increase the exibility and parallelism of the biochips. Figure 9 shows the proposed architecture.
The presented architecture in Figure 9 is a twodimensional array of Con gurable Bio-Cell (CBC). Each CBC is analogues to FPGA logic block that contains the primary operations of the biochemical treatments. In this architecture, input and output ports of chemical material are the same as the FPGA I/O pins too. The electrodes are used to control the droplet routing that travels among the CBCs. This architecture is called Programmable Bio-Cell Matrix (PBCM). Figure 10 shows the internal structure of a CBC that contains the following elements: -A mixing module that is specialized with electrodes 7-13;
-Input-output port of mixing module or I/O mixer that is specialized with electrodes 16-17; -Mixer hold module that is specialized with electrodes 14-15; -Three Split-Store-Detection (SSD) modules that are electrodes 21-23; -Input-output port of SSD modules or I/O SSD that are electrodes 18-20; -Routing electrodes (1-6).
In Figure 10 , electrodes 1-3 of each cell are used to transfer droplets in horizontal buses, and electrodes 4-6 are used to transfer droplets in vertical buses.
These electrodes should be indexed in all the CBCs in the same order because all electrodes of the CBCs with the same index are connected to one controlling pin. In this structure, the sameindex electrodes are activated simultaneously with one controlling pin. Electrodes 7-14 should create a mixing unit, and droplets which should be mixed must enter and mix in these units from various routes.
Electrodes 7-13 are common in all cells and are activated at the same time; however, electrode 14 is used to store a mixed droplet in each cell and is controlled with di erent pins in various cells. Electrode 16 is input-output ports for mixing module, which is used to enter or exit droplet. It should be controlled with di erent pins in various cells. This ability should exist so that one droplet in a cell can exit mixing module, while other droplets remain in other cells for some time steps.
Electrodes 21-23 are used for storing, splitting, and detecting droplets and are controlled with di erent pins in various cells. If, during executing assays, droplets need to be detected by external sources; these detectors should be located above SSD electrodes and detect droplets in some time steps. Storing operation requires a droplet to enter a SSD module (for example, electrode 21) and remain in place. According to Figure 10 , for splitting operation, the initial position of droplet, which will be split, is on a vertical transport bus next to an SSD modules I/O cell (for example, electrode 5). The cell on the transport bus is activated throughout the split. The I/O cell (electrode 18) is then activated, which stretches droplet to cover both cells.
Next, the SSD modules' hold cell is activated, and the I/O cell is deactivated; this splits the droplet into two separate droplets on the hold cell and in the transport bus. Connections between SSD modules and vertical routes should be made by electrodes 18-20, which are controlled with di erent pins in various cells.
Electrodes connecting cells with a circular area and connecting electrodes between internal cells can all be controlled via common pins to transfer droplets between cells without overlapping.
In Figure 10 , a PBCM with 4 cells is shown whose CBCs have a similar structure to those in Figure 8 in which all the CBCs are connected together using the routing paths. Input/output sources and dispensers are located around the chip. Regarding the above explanations, the biochip of Figure 10 can perform parallel 8 mixes, 12 splits, and store operations on minimum 20 droplets. This plan is useful for large assays with lots of operations because the time of assays can be shortened by parallelizing the operations. All the MIX modules have been initialized with identical pin numbers so that all MIX operations on the chip surface can be run simultaneously, leading to the parallelization of the MIX operation. On the other side, for small assays or the ones that do not need all the cells, extra cells can be deactivated to reduce power consumption.
It is worth noting that the internal structure of CBCs can be customized for target assays. For example, CBCs can be considered with more MIX modules for the assays with a large number of MIX operations (Figure 11(a) ), and they can be designed with more number of SSD modules when the assays have a large number of SSD operations, as shown in Figure 11 (b).
Design ow for the proposed architecture
Input of a micro uidic biochip CAD ow is an assay. This assay is broken down to a few basic operations and converted to a Directed Acyclic Graph (DAG) that can be easily de ned and automated, normally. In assay DAG, nodes represent the set of operations such as merge, MIX, split, transport, detect, etc., and edges show the droplet transfer between the operation modules. For example, sequencing graph for the mixing stage of PCR with 7 MIX modules is shown in Figure 12 [19] .
Static Synthesis Simulator (SSS) [20] is a widely used academic synthesis framework developed at UC Riverside to develop and evaluate the CAD modules for digital micro uidic biochips [14] . SSS is a full synthesis ow (e.g., scheduling, placement, routing) of assay graphs with simulation and GUI toolboxes. We revised SSS according to our architecture. The main part of SSS that should be updated for a new architecture is pin mapping module. Pseudo code of the pin-mapping algorithm is shown in Figure 13 .
In the following paragraphs, detailed description of the pin-mapping algorithm will be described:
Step 1: Pin numbers will be assigned to the electrodes in the rows between the biochip modules;
Step 2: Pin numbers will be assigned to the electrodes in columns between biochip modules; Figure 14 . PBCM DMFB routing algorithm.
Step 3: Unique pin numbers will be assigned to the electrodes of the MIX and the detection modules;
Step 4: Pin numbers 7 to 13 will be shared between all MIX modules and assigned to the corresponding electrodes;
Step 5: Pin number of reservoirs' I/O electrodes that are connected to the chip will be assigned. Another part of SSS that should be revised for the proposed architecture is routing algorithm. Figure 14 represents the revised routing algorithm.
The input of this algorithm is a sequencing graph of the bioassay that is generated in the rst stage of synthesis ow, and the output is a sequence of pinactivating process to specify the path of the droplets. The sequencing graph describes the nodes and their relations in the bioassay to the assay rules. In fact, the routing stage determines how the droplets move between the placed modules on the chip surface. In the following paragraphs, a detailed description of the PBCM DMFB routing algorithm will be described:
Step 1: Sort the operations of the assay. Get the nodes that need to be routed; then, sort and get dependencies between nodes.
Step 2: Perform actual routing of droplets based on the number of nodes in the original (parent).
Step 2-1: Do actual routing of droplets primarily based on the number of subnodes (child).
Step 2-1-1: If the node is not OUTPUT module (it is input or basic module), the droplet should exit the module and enter the column. Routing is connected to the module (the electrodes numbered by 0-2 in 9).
Step 2-1-2: If the child's routing column is not the same as the column number of the parent module, droplet should be routed from its module to the column of child's module.
Step 2-1-3: If the child's column is the same as the column number of the parent module, droplet moves in the routing column to achieve destination module. In addition, the hold pin of all compound modules will be active.
Step 2-1-4: At this point, the routing is fed to the output reservoir.
Experimental results
The proposed micro uidic architecture in SSS toolkit [17, 21] is implemented to evaluate the e ciency of this architecture. The proposed architecture is compared with the presented biochip in [8] based on direct-addressing (DA) of electrodes with controlling pins and addressed method in [6] based on the programmable method with considering pin-constrained (FPPC). The proposed method in this paper is called PBCM in experimental results. We have used 2*2 CBC structure to execute assays. Various metrics are considered that can be classi ed in three groups: fabrication cost, timing, and resource usage. A comparison of the presented architecture and design ow in terms of metrics is described in the following subsections.
Fabrication cost
In this subsection, the proposed architecture and design ow can be evaluated in terms of the number of pins and electrodes that are e ective in area and cost of micro uidic biochip. Comparison parameters for this phase include maximum area of micro uidic chip (dimension of micro uidic matrix), number of electrodes used in the array, and the number of control pins.
Fourteen di erent assays are selected as benchmarks for better evaluation.
As mentioned before, the number of pins is the most signi cant limitation in micro uidic biochips, and reducing the number of controlling pins is an important challenge. In Table 1 , the proposed architecture is compared in terms of the number of control pins. In Table 1 . Comparison of the suggested method with [6, 8] in terms of the number of control pins. As can be seen in Table 1 , the number of required pins in the proposed architecture is improved by 83.7% and 21% as compared to DA and FPPC methods, alternatively. Results of this table represent that, in the proposed architecture, better functionality and higher exibility can be achieved with a few number of physical pins (on average). Increasing the number of PCB layers always accompanied by high costs and fewer number of control pins in the PBCM architecture reduces manufacturing costs of biochips considerably. Table 2 compares the chip area (dimension) and number of electrodes in the proposed architecture (PBCM) with existing architectures (DA and FPPC). In this table, column array dimension shows the number of row and columns in the biochip, and column #UE represents the number of used electrodes. The last two columns represent the improvement of the number of used electrodes of BPCM rather than conventional methods (DA and PBCM).
As can be seen in Table 2 , the number of required electrodes in the proposed architecture is improved by 22.69% as compared to DA, but increased by 4.3% compared to FPPC. A higher level of exibility of PBCM is earned with 22.69% improvement in electrodes as compared to DA and 4.3% compared with FPPC. Moreover, the most signi cant cost of a micro uidic biochip is the number of pins, and overhead in the number of electrodes is more tolerable for designers. 
Timing
In the second stage of experiments, the proposed architecture has been examined and compared from the timing perspective. Comparison parameters for this phase include routing delay, scheduling delay, and simulation time. Table 3 shows the results of scheduling, routing, and simulation times for two PBCM and FPPC architectures. As shown in Table 3 , the timing parameters are better for the proposed architecture than those for FPPC. This improvement resulted from the parallelism capability in PBCM. In the proposed method, merging, split, and detection operations are done separately in distinct modules and blocks; however, all of them operate in parallel with the same pins. In each assay, related droplets with related operations enter a CBC block and are stored in SSD modules on the same CBC blocks after performing the operations. In addition, droplets are kept in CBC blocks and moved to other CBC blocks to merge with other droplets or split to carry out other operations or detection, if necessary. Therefore, the number of droplets able to carry out parallel operations in the entire DMFB will increase.
Since this chip does some mixing and operations are detected separately and in parallel, the execution time of assays, especially huge assays, will decrease. On the other hand, our proposed biochip can run any assay, especially assays with a large number of MIX operations on one chip, and it is not necessary to increase dimension of chip for larger assays. In addition, our method can reduce power consumption, because, for small assays, the unused electrodes or CBC blocks can be o .
According to Table 3 , the execution time of routing and simulation algorithms worsened for in-vitro assays in PBCM architecture due to their low number of operations. However, it is more e cient for protein assays (protein assays consist of many detection and MIX operations). As a result, PBCM architecture has higher e ciency for assays with a large number of operations.
Resource usage
In the last phase of experiments, the proposed architecture is studied from resource consumption perspective. Table 4 shows the experimental results in terms of the used resources (SSD and MIX modules) for the attempted benchmarks in FPPC and PBCM architectures.
As can be seen in Table 4 , the number of used SSD and MIX modules is reduced for the proposed architecture in comparison with FPPC architecture by about 25.07% and 28.01%, respectively. As a result, PBCM architecture is used to optimize MIX and SSD modules. Table 4 . Comparison of the suggested method with [6] in terms of the number of MIX and SSD modules.
